The objective of our study is to demonstrate the interest of early administration of recombinant erythropoietin in trauma patients

Could an early use of rHuEPO (recombinant Human ErythroPOietin ) be lead to an individual benefice on transfusion savings after traumatic surgery?

Inclusion Criteria:

• Patients between 18 to 65 years old
• Patient with an ASA 1 or 2 (ASA 1 corresponding to a patient in perfect health and ASA 2 to a patient with moderate involvement and well controlled organ function)
• patient presenting at least one of the following fractures: Basin and / or femur with surgical indication, associated or not with other fractures.
• patient with hemoglobin between 9 and 13 g / dl at the time of admission on trauma department

Exclusion Criteria:

• patient with contraindication to synthetic erythropoietin
• Patient with intravenous iron contraindication
• pregnant patient or with a risk of pregnancy
• patient who has not given his consent or does not understand the protocol
• Patient with hemodynamic instability
• patient participating in another research protocol for less than 3 months.